- Home
- CERO vs ADXN Comparison
CERO vs ADXN Comparison
Compare CERO & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- ADXN
- Stock Information
- Founded
- CERO 2017
- ADXN 2002
- Country
- CERO United States
- ADXN Switzerland
- Employees
- CERO N/A
- ADXN N/A
- Industry
- CERO
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- ADXN Health Care
- Exchange
- CERO Nasdaq
- ADXN Nasdaq
- Market Cap
- CERO 8.4M
- ADXN 8.0M
- IPO Year
- CERO N/A
- ADXN N/A
- Fundamental
- Price
- CERO $2.34
- ADXN $7.97
- Analyst Decision
- CERO
- ADXN Strong Buy
- Analyst Count
- CERO 0
- ADXN 1
- Target Price
- CERO N/A
- ADXN $30.00
- AVG Volume (30 Days)
- CERO 80.5M
- ADXN 25.1K
- Earning Date
- CERO 02-20-2025
- ADXN 11-22-2024
- Dividend Yield
- CERO N/A
- ADXN N/A
- EPS Growth
- CERO N/A
- ADXN N/A
- EPS
- CERO N/A
- ADXN 0.06
- Revenue
- CERO N/A
- ADXN $701,260.00
- Revenue This Year
- CERO N/A
- ADXN N/A
- Revenue Next Year
- CERO N/A
- ADXN N/A
- P/E Ratio
- CERO N/A
- ADXN $1.03
- Revenue Growth
- CERO N/A
- ADXN N/A
- 52 Week Low
- CERO $2.22
- ADXN $6.45
- 52 Week High
- CERO $1,280.00
- ADXN $27.90
- Technical
- Relative Strength Index (RSI)
- CERO 32.54
- ADXN 50.40
- Support Level
- CERO $2.83
- ADXN $7.28
- Resistance Level
- CERO $3.50
- ADXN $8.36
- Average True Range (ATR)
- CERO 1.13
- ADXN 0.74
- MACD
- CERO 0.05
- ADXN 0.05
- Stochastic Oscillator
- CERO 1.43
- ADXN 50.26
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.